Invest in a World-First Heart Disease Breakthrough with Cholrem Pty Ltd Brisbane, Australia – February 2025 Cholrem Pty Ltd, an Australian pharmaceutical innovator, has developed Cavadex—the world’s first over-the-counter treatment proven to reverse heart disease. With heart disease claiming 18 million lives globally each year, including 50,000 in Australia, our groundbreaking solution is poised to transform healthcare and deliver exponential growth. We’re on the cusp of a major milestone: an anticipated Trump Administration announcement is expected to turbocharge our U.S. exports, projected to leap from $7 million in 2024 to over $600 million in 2025. To meet this surging demand, we’re scaling up with a state-of-the-art manufacturing facility in Brisbane. We’re now offering a rare chance to join this high-growth journey as a shareholder in Cholrem Pty Ltd. This is an opportunity to invest in a company at the forefront of medical innovation with blockbuster potential.
Investment Opportunity Shares Available: 10 limited equity stakes Price: $100,000 per 1% share Ownership Benefits: As a shareholder, you’ll own a direct percentage of Cholrem Pty Ltd and receive quarterly dividends tied to our sales performance.
Projected Returns: Share value is forecast to rise over 800% within 10 months, driven by U.S. market expansion and global adoption. Dividends are expected to reach approximately $1 million per 1% share by December 2025, based on conservative sales projections.
Why Invest Now? Proven Product: Cavadex has already generated $7 million in 2024 sales through organic demand, with patients and clinicians worldwide reporting life-changing results. Massive Market: Targeting just 1% of the U.S.’s 100 million at-risk population could yield $375 million monthly—our growth trajectory is steep and immediate.
Strategic Timing: The upcoming U.S. policy shift, combined with our production ramp-up, positions Cholrem for a seismic revenue surge in 2025. This is a once-in-a-lifetime chance to back an Australian company disrupting a trillion-dollar health crisis. With only 10 shares available, this exclusive offer won’t last long. Secure your stake in Cholrem Pty Ltd and be part of a medical revolution with extraordinary financial upside
Singapore 
